Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies

A method of treating a retinal disease associated with hVEGF in a subject in need thereof, comprising:

• administering surabgene lomparvovec to the suprachoroidal space of an eye of said subject, wherein said administration of surabgene lomparvovec is at a dose in an amount of 1×1012 GC/eye to 2×1012 GC/eye;
• and
• topically administering difluprednate or a pharmaceutically acceptable salt thereof to the eye of said subject prior to and after said administration of surabgene lomparvovec.

A method of treating a retinal disease associated with hVEGF in a subject in need thereof, comprising:

• administering surabgene lomparvovec to the suprachoroidal space of an eye of said subject, wherein said administration of surabgene lomparvovec is at a dose in an amount of 1×1012 GC/eye to 2×1012 GC/eye;
• and
• topically administering prednisolone or a pharmaceutically acceptable salt thereof to the eye of said subject prior to and after said administration of surabgene lomparvovec.